Crystalys Therapeutics has emerged from its cocoon with $205 million first-round financing and a potential treatment for gout that is already in phase 3 testing. The Series A, co-led by Novo Holdings, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback